SBRT Followed by Nivolumab/Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
International Journal of Radiation Oncology, Biology, Physics
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Phase I Randomized Trial of Stereotactic Body Radiotherapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma
Int. J. Radiat. Oncol. Biol. Phys 2022 Sep 12;[EPub Ahead of Print], A Juloori, RR Katipally, JM Lemons, AK Singh, R Iyer, JR Robbins, B George, WA Hall, SP Pitroda, F Arif, J Fung, A Pillai, CY Liao, M Sharma, SL LiauwFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.